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Abstract
1.	Background and significance of the study: 
This study describes the epidemiology of haemophilia in the State of Maharashtra, India. Haemophilia is a rare hereditary bleeding disorder with a prevalence of 6 per 100,000 population and an incidence of 1 per 10,000 male births (Chandy, 1990; World Health Organization, 1996). Haemophilia occurs due to a deficiency in coagulation factor, resulting in abnormal haemostasis (Pollak and High, 2003). The disorder manifests as frequent and spontaneous bleeding episodes in joints or soft tissues. Haemorrhagic episodes are treated by replacement therapy with virus-inactivated plasma concentrates of the deficient coagulation factor (Factor VIII in case of haemophilia A or classical haemophilia and Factor IX in case of haemophilia B or Christmas disease). Before the advent of replacement therapy haemophilia-associated morbidity, mortality and disability were due to excessive bleeding, particularly into weight-bearing joints and the central nervous system (mainly intracranial haemorrhages) (Ramgren, 1962; Ikkala, 1982). The median age of death for persons with haemophilia in the United States was about 11.4 years between 1831 and 1920 (Soucie et al., 1999). After the 1960s, as availability of clotting factor concentrates and treatment modalities improved, haemophilia-related mortality decreased substantially and yielded nearly normal life expectancy (Larsson and Wiechel, 1983; Larsson, 1985; Johnson et al., 1985, Aronson, 1988; Jones and Ratnoff, 1991; Chorba et al., 1994). However, in the 1980s, deaths from HIV infection or hepatitis decreased the survival of haemophilia patients (Ikkala et al., 1982; Smit et al., 1989; Triemstra et al., 1995; Soucie et al., 2000). With improvement in viral inactivation methods, clotting factor concentrates are now used prophylactically in many developing countries, altering the profile of haemophilia from a “limb-threatening”, “life-limiting” condition to a chronic but manageable condition with near normal life expectancy (O’Mahony, 2004).
Haemophilia is not a disease of public health relevance in India. Like other developing countries, the focus of public health services in India is on the control of highly prevalent communicable diseases, health promotion and family welfare services (National Health Policy, 2002; http://mohfw.nic.in/np2002.htm). In contrast, haemophilia is a rare condition, which is non-communicable, chronic and extremely expensive to treat. Thus, this condition is not a public health priority and does not attract any government resources. Under such circumstances, data collection for haemophilia acquires very low priority. Consequently there is very little information on the disorder and its trends in the population. 
The Hemophilia Federation, India (HFI), an organization administered primarily by patients, imports and distributes clotting factor concentrates (CFCs) through its network of chapters spread throughout the country. In addition the organization carries out awareness, counselling and patient education activities (Hemophilia Federation, India; http:\\www.hemophiliaindia.net). The Indian scenario is characterized by chronic shortage of treatment products, incomplete treatment due to poor purchasing power of patients and extreme physical, economic and emotional trauma for patient and his family members. Furthermore, due to economic reasons patients repeatedly use blood and blood products as a cheaper alternative thus exposing themselves to the risk of transfusion related infections. Poor use of factor concentrates manifests as progressive crippling disability, the extent and associated social costs of which are unknown. 
Haemophilia may not be an insignificant problem. With a population denominator of 1,028,610,328 (Census of India, 2001; http://www.censusindia.net) and prevalence of 6 per 100,000 (Chandy, 1990; World Health Organization, 1996), the estimated number of Indian haemophilia A patients would be 61,621. Unlike many other hereditary diseases, the reproductive fitness is not affected in patients of haemophilia. World wide it is well established, that with the improvement in medical services (as is being witnessed in India), the prevalence of haemophilia increases (Baird and Scriver, 1998). Prenatal diagnosis of haemophilia, the primary tool to control affected births, is not only expensive but also is associated with the gender-sensitive implications of the disorder, since haemophilia is transmitted from mother to the son. 
With this backdrop, the aim and objectives of the thesis were as follows. The thesis has been divided into two parts. Part A describes the epidemiology of haemophilia, while part B deals with the genetics of the disorder.


2.	Part A: Aim and Objectives
The aim of this part of the thesis was to compile an epidemiological profile of haemophilia, from secondary data collected in the State of Maharashtra, India. 
2.1.	Objective I
To compile data on haemophilia from secondary data and utilize this to describe the epidemiology of haemophilia in the State of Maharashtra.
2.2.	Objective II
To determine the age at diagnosis for patients with haemophilia A and haemophilia B of varying severity and to determine the influence of occupation and income of parents, place of residence, family history and age at first bleed in determining age at diagnosis of severe haemophilia A patients.
3.	Part B: Aim and Objectives
The aim of this part of the thesis was to examine the genetics of haemophilia.
3.1.	Objective III
To determine the influence of family history on the size of families with haemophilia
3.2.	Objective IV
To determine the heterozygosity of RFLP markers in the FVIII gene.
4.	Materials and Methods
4.1.	Part A: Materials
4.1.1.	Data sources
CFCs are distributed exclusively through the Chapters of the HFI. Hence, CFC usage records along with clinical records and laboratory reports (where available) from the three Chapters of the HFI in the State of Maharashtra were used as data sources. Secondary data was also collected from a tertiary care facility at Mumbai where patients were using blood or blood products. Data was collected for patients between 1989 and 2000. 
4.1.2.	Mode of ascertainment of cases
The index cases were defined as physician diagnosed cases of haemophilia A or B, which was further verified from CFC usage records, records of laboratory diagnosis and registration records. 
4.1.3.	Checks for duplicate data and patient confidentiality issues
Data was coded to maintain confidentiality after ensuring that individual information was recorded only once.
4.1.4.	Variables
Data was collected for a total of 13 variables, which included socio-demographic, clinical and genetic variables.


4.2.	Part A: Methods
4.2.1.	Compilation of a haemophilia database for Maharashtra: 
Data was available for a total of 1467 patients. These data were compiled as a Haemophilia Database of Maharashtra (HDM).
4.2.2.	Data entry and analysis
Data was entered into Microsoft Excel worksheet (version 2000). 
1.	For descriptive epidemiology, the information compiled in the haemophilia database was analyzed and presented using descriptive statistics. In order to determine whether there were any changes in some key variables (diagnosis of severe patients, age at registration and diagnosis, place of residence) over the decade, patients were divided into two registration cohorts. Cohort I consisted of patients who had registered during the first half of the decade (between 1991 to 1995). Cohort II consisted of patients who had registered later in the decade (between 1996 to 2000), when haemophilia services had been in place for more than five years in the State. Differences between the groups were analyzed using chi-square test. 
2.	Factors influencing age at diagnosis for severe haemophilia A patients were determined through analysis of occupation and income of parents, place of residence, family history and age at recall of first bleeding episode on age at diagnosis. Data were analyzed by applying chi-square and one-way ANOVA tests. 

4.3.	Part B: Materials and methods
4.3.1.	Analysis of pedigrees 
Pedigrees appended to clinical records were used to determine the influence of family history on family size of families of patients with haemophilia. Out of the total 1467 records for patients, 658 records had appended pedigrees. Family size and family composition were the two measures used. Family size was defined as the number of live births per woman. Family composition indicated number of male and female children born to a woman. The impact of family history on family size was determined by comparing family size of women without history, women with history, women with affected fathers and women with other affected relatives. Family size of families with haemophilia was compared to determine the influence of family history on family size across one generation. Parents of patients registered after 25 years of age represented the older generation of parents, while parents of patients registered between 8 to 12 years of age represented younger generation of parents. To determine the impact of family history on number of affected sons across generations, parents were divided into two groups representing older and younger generations. Parents of patients registered after 20 years of age represented the older generation of parents, while parents of patients registered before 10 years of age represented younger parents.
4.3.2.	Collection of blood samples 
Blood samples (5 ml) were collected in EDTA coated bulbs from control females (females with no prior history of haemophilia) (n = 56). Blood samples were also collected from 8 families without any haemophilia patients and from families with one or more patients with haemophilia (n = 10) after informed consent. 
4.3.3.	Ethical considerations
All invasive procedures were done after obtaining informed consent. The carrier detection protocol was reviewed by institutional ethical and scientific committee, which included representative of the haemophilia chapter. Pre and post-test couselling was done for families approaching the researcher for carrier detection. 
4.3.4.	Isolation of DNA, amplification and restriction digestion
Isolation of DNA from blood samples was carried out following universal biosafety precautions. DNA amplification was carried out for the HindIII and BclI RFLPs in the FVIII gene using polymerase chain reaction (PCR) (Kogan et al., 1987; Surin et al., 1990). The amplified products were digested according to the manufacturer’s instructions and electrophoresed on either agarose or polyacrylamide gels. The gels were stained with ethidium bromide. The image was stored in a Bio Rad gel documentation system (Version 4) and analyzed to determine the RFLP profiles. Genetic analysis was conducted for controls and patient families.



5.	Results 
5.1.	Descriptive epidemiology 
Data were available for a total of 1467 patients. Ratio of haemophilia A to haemophilia B patients was 4.2:1, with majority (85%) being severe patients with FVIII deficiency. Age distribution revealed that majority (77%) of severe haemophilia A patients were under 20 years of age. There was a reduction in the number of severe haemophilia A patients above 20 years. Time trends of case registrations revealed a 91% decrease in case registrations over the decade from the year 1989 to 2000. The number of cases being registered remained stationary at around 172±33 per year from 1995-2000. Spot map analysis revealed clustering of cases around the haemophilia clinics, and large areas of the State without any patients. Data regarding active usage of services revealed low utilization (29%). Of the active users majority were severe patients (43%) and more than 50% patients 

were residents of urban areas. 


The impact of establishing haemophilia services was examined by analyzing data on two cohorts of patients. The analysis showed a significant increase in the number of severe haemophilia A patients being registered in the second half of the decade (2 = 31.38, P < 0.001) and a significant increase in patients from rural areas (2=24.8, P < 0.001). There was an increase in the number of cases diagnosed prior to one year of age in the second half of the decade (2=12.69, P < 0.001). The number of patients using specialized haemophilia care prior to the age of one year also showed a significant increase in the second half of the decade (2 = 29.63, P < 0.001).
5.2.	Influence of occupation and income of parents, place of residence, family history and age at first bleed in determining age at diagnosis of severe haemophilia A patients
Early diagnosis avoids irreversible arthropathic changes and reduces the frequency of life threatening bleeds in patients with severe FVIII deficiency. In developed nations majority of the severe patients are diagnosed before one year of age (Conway and Hilgartner 1994, Ljung et al 1994, Pollmann et al 1999, Chambost et al 2002). The age at diagnosis and influence of occupation and income of parents, place of residence, family history and age at first bleed in determining the age at diagnosis was examined. Data revealed that 24% patients were diagnosed during the first year of life, and another 32% were diagnosed till five years of age. Nearly 11% severe patients were diagnosed beyond 20 years of age. Analysis of data on reported age at first bleed (indicating parental awareness about the signs of haemophilia) was significantly different for patients of haemophilia A and B (3.3±5.9 and 4.7±6.4 years 
respectively, z = 2.29, P<0.05) and amongst patients with varying FVIII severity levels. The mean age at diagnosis in case of haemophilia A and B patients was not significantly different (9.3±11.6 and 9.1±9.8
 years respectively, z = 0.19
). However, there was significant difference in age at diagnosis in FVIII deficient patients based on severity of the condition (severe vs moderate, z = 2.94, P < 0.01; severe vs mild, z = 5.44, P < 0.001). Twenty seven percent patients were diagnosed with a delay of five years or more after the first bleeding signs were reported. Twenty one percent patients had used specialized haemophilia care services for the first time after being diagnosed with a gap of more than 5 years in between. The factors significantly influencing age at diagnosis were :  place of residence of patients (access to haemophilia care facility) (χ2 = 4.28, P <  0.05. One way ANOVA, F3,338 = 2.811, P = 0.039) and reported age at first bleed (indicating awareness about the symptoms of the disorder) (χ2 = 50.41, P<0.001. One way ANOVA, F3,245 = 24.388, P=0.000). Socio-economic status of parents (χ2 = 2.98, One way ANOVA, F4,227 = 0.922, P = 0.452) and family history of the disorder   (χ2 = 0.05. One way ANOVA, F2,251 = 0.044, P = 0.957) did not have significant influence on the age at diagnosis.
5.3.	Influence of family history on the size of families with haemophilia
This part of the work utilized pedigree data to address the question of whether knowledge of haemophilia as defined by experience of haemophilia in an affected family member influences the number of children especially sons born in the family. Parents were categorized into two groups as older parents (group I) and younger parents (group II). The number of children in families who had reported history of haemophilia was 2.91.5, which was significantly less than the size of families without history (3.61.9, z = 6.36,   P < 0.001). Family size of women whose father had haemophilia (2.51.3) was significantly less than that of women without history (3.61.9, z = 7.23,   P < 0.001). The number of children born to women who reported haemophilia in a brother or other maternal relative (3.01.5) was significantly more than the family size of obligate carriers whose father had haemophilia (z = 3.1,       P < 0.05). These data suggested that the reproductive decision-making was influenced when a daughter had experienced haemophilia in her father. However, when the affected member was a brother or another maternal relative, these experiences did not affect the family size. 
With respect to impact of family history on family size, the average size of families without history of haemophilia in the older group of parents (group I) was 4.51.76 as compared to 2.670.89 for younger parents (group II). In case of families with history of the disorder, older parents (group I) had the average family size of 3.971.79 as against 2.910.86 for younger parents (group II). There was significant reduction in the number of children of both sexes born to younger (group II) versus older (group I) parents irrespective of family history of haemophilia. In families with history of haemophilia, the proportion of families with more than one affected son in older and younger generations remained unchanged  (2=1.43) suggesting a compensatory response to the high mortality associated with the disorder in India.
5.4.	Informativeness of RFLP markers in the FVIII gene
The control of genetic diseases is through prenatal diagnosis. Carrier detection is the first step towards prenatal diagnosis. This chapter of the thesis examined the informativeness of two RFLP markers used for linkage analysis, viz., HindIII RFLP in intron 19 and BclI RFLP in intron 18. A total of 132 DNA samples from as many individuals were analyzed for these two RFLPs. The frequency of (-) and (+) alleles for the HindIII RFLP was 60% and 40% respectively. The allele frequency was 42% and 58% in case of (-) and (+) alleles respectively for the BclI RFLP. The heterozygosity was 48% (11 out of 23) and 45% (10 out of 23) for the HindIII and BclI RFLP markers respectively. Utilizing these two RFLPs, carrier detection could be accomplished for 50% females approaching the researcher for carrier detection.
6.	Summary of key findings of the study
The majority of patients were severe haemophilia A patients under 25 years of age, who had been primarily diagnosed in and around those cities where haemophilia clinics were located. Over time, diagnosis and registration of patients from rural areas had increased significantly, indicating the increased awareness about haemophilia, possibly due to the awareness activities of the national haemophilia organization. From the records, only 20% of the estimated number of haemophilia A and 17% of the estimated haemophilia B cases in the State could be calculated.  
Annual case registration trends showed a plateauing at 172±33, possibly reflecting that case registrations had been achieved from the areas surrounding the hemophilia clinics. Case referrals were primarily of severe haemophilia patients, reflecting under-diagnosis and lack of awareness about the signs and symptoms of mild and moderate haemophilia. There were improvements in some key indicators over the decade, notably, improved referral of severe patients, improvement in age at diagnosis and improvement in the age at which the patients were using specialist haemophilia care for the first time. These data imply that despite the fact that haemophilia treatment is expensive, NGO activities in the form of awareness campaigns and provision of concentrated specialist care can bring about an improvement in the situation.
The age at diagnosis was significantly delayed in a large majority of cases. For 20% of patients, at least 5 years had lapsed from definitive diagnosis of haemophilia till the time patients accessed haemophilia clinics. This indicated that there were various constraints for accessing haemophilia care (which have not been addressed in this study). The factors significantly influencing the age at diagnosis for severe haemophilia A patients were accessibility to haemophilia clinics and awareness of parents about symptoms of the disorder. The latter finding suggests that there is need for continuous awareness activities amongst medical practitioners, in order to facilitate earlier detection of cases.
One of the ways of controlling hereditary disorders is through the provision of genetic counselling services. The study showed that, as seen in the general population, families with haemophilia had also witnessed a reduction in family size over time. However, families with history of haemophilia had more affected sons than families who had not experienced haemophilia. Provision of psychosocial support and genetic counselling will help the affected families to make informed decisions about their families.
Carrier detection is the first step towards prenatal diagnosis. In this study, the HindIII and BclI RFLP markers used for carrier detection were heterozygous in 48% and 45% women in haemophilic families respectively. These two markers were informative for 50% families with haemophilia.
7.	Conclusions 
This is the first study to present information on the epidemiology of haemophilia in Maharashtra, between 1989 and 2000. The results demonstrate that CFC usage and clinical records of the HFI can be used for a passive surveillance system. Variables that have been analyzed can be collected by lay persons, and analyzed at a technical facility. The data could then be used by the haemophilia organization to showcase the impact of their activities and justify further funding to improve services for haemophilia patients.
The study findings revealed that a patients’ organization with limited resources, could bring about positive changes for people with haemophilia. In absence of such an organization, haemophilia patients are unlikely to receive public health support for treatment. 
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